Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.91% | -17.46% | -50.87% | -41.35% | -13.55% |
| Total Depreciation and Amortization | -14.81% | -88.08% | -15.56% | -8.90% | 3.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.39% | -23.37% | -43.56% | -53.05% | -55.99% |
| Change in Net Operating Assets | 139.96% | -492.15% | -29.40% | 108.63% | 201.84% |
| Cash from Operations | -18.97% | -65.48% | -83.68% | -67.09% | -26.14% |
| Capital Expenditure | 3.13% | 17.08% | 3.78% | 23.75% | 43.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83.75% | 171.44% | 114.21% | 106.74% | -144.38% |
| Cash from Investing | 83.57% | 171.23% | 113.91% | 106.45% | -142.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.16% | -89.58% | -12.69% | -13.62% | 213.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -67.19% | -67.19% | -67.19% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 214.62% | 95.39% | 26.87% | 26.09% | -118.77% |
| Cash from Financing | -6.77% | -90.93% | -25.81% | -26.53% | 102.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,588.65% | -134.57% | -53.09% | 686.12% | 93.87% |